tadalafil has been researched along with Hypertension, Pulmonary in 142 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (14.79) | 29.6817 |
| 2010's | 108 (76.06) | 24.3611 |
| 2020's | 13 (9.15) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, Y; Geng, H; Guo, L; Huang, Y; Huang, YY; Li, Z; Luo, HB; Wu, D; Zhang, C; Zhang, T | 1 |
| Aisa, HA; Gong, X; He, Y; Jiang, H; Jiang, X; Li, J; Liu, Z; Shen, J; Shi, J; Suo, J; Tian, G; Wang, Y; Wang, Z; Wu, C; Wu, J; Xu, Y; Xu, Z; Yang, R; Yang, X; Zhang, R; Zhang, X; Zhu, W; Zou, X | 1 |
| Crook, S; Dorn, ML; Frank, B; Hite, MD; Issapour, A; Ivy, DD; Krishnan, US; Rosenzweig, EB | 1 |
| Hountras, P; Lane, T | 1 |
| Bai, C; Giannakoulas, G; Hohenforst-Schmidt, W; Huang, H; Karapantzou, C; Kioumis, I; Kosmidis, C; Matthaios, D; Petanidis, S; Petridis, D; Pitsiou, G; Sardeli, C; Tsakiridis, K; Zarogoulidis, P | 1 |
| Deprest, J; Kumar, S; Mol, BW; Russo, F; Turner, JM | 1 |
| Dohi, K; Hirayama, M; Ito, H; Kabwe, JC; Ko, H; Maruyama, J; Maruyama, K; Mashimo, T; Mitani, Y; Miyasaka, Y; Nishimura, Y; Ohashi, H; Okamoto, R; Oshita, H; Otsuki, S; Oya, K; Sawada, H; Tsuboya, N; Yodoya, N; Zhang, E | 1 |
| Cockrill, BA; Ruopp, NF | 1 |
| Humbert, M; Weatherald, J | 1 |
| Henry, DS; Pellegrino, RG | 1 |
| Bender, SB; Jaffey, JA; Kong, LR; Leach, SB; Reinero, CR; Wiggen, KE | 1 |
| Aso, K; Hokuto, I; Kitazawa, T; Migita, O; Mizuno, M; Tsuzuki, Y; Yamamoto, H | 1 |
| El-Hajjar, M; Kumar, S; Zheng, WQ | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Abston, E; Berman, J; Farber, HW; Govender, P; Hon, S; Lawrence, R | 1 |
| Cascino, TM; McLaughlin, VV | 1 |
| Risbano, MG; Rivera-Lebron, BN | 1 |
| Allard, M; Blair, C; Feldman, J; Gillies, H; Keogh, A; Oudiz, RJ; Shapiro, S; Tislow, J; Torres, F | 1 |
| Großer, C; Hoenicka, M; Hofmann, HS; Lang, G; Lehle, K; Neu, R; Ried, M; Szöke, T | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Chin, K; Damico, R; Girgis, RE; Hassoun, PM; Khair, RM; Kolb, TM; Mathai, SC; Mercurio, V; Minai, OA; Mukherjee, M; Sato, T; Tedford, RJ; Torres, F; Zamanian, RT | 1 |
| Kobayashi, N; Murakami, M; Suzuki, N; Tajima, K; Taketsuna, M; Yamazaki, H | 1 |
| Ahmadi, A; Bigdelian, H; Ghaderian, M; Hosseinzadeh, M; Sabri, MR; Shoja, M | 1 |
| Thenappan, T; Weir, EK | 1 |
| Argiento, P; Badagliacca, R; Correale, M; D'Alto, M; Ghio, S; Greco, A; Lo Giudice, F; Paciocco, G; Prediletto, R; Romeo, E; Vizza, CD | 1 |
| Okada, S; Sugawara, A; Takeuchi, S; Watanuki, Z; Yamagata, S | 1 |
| Cracowski, JL; Humbert, M; Khouri, C; Lepelley, M; Montastruc, F; Roustit, M | 1 |
| Chang, M; Gall, H; Grünig, E; Halank, M; Mielniczuk, L; Orozco-Levi, M; Tanabe, N; Vachiéry, JL; Vogtländer, K | 1 |
| Tanabe, N | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Chabot, F; Chaouat, A; Gomez, E; Guillaumot, A; Petitpain, N; Ribeiro Baptista, B; Valentin, S; Yelehé-Okouma, M | 1 |
| Barberá, JA; Blair, C; Frost, AE; Hoeper, MM; Langley, J; Rubin, LJ; Vachiery, JL | 1 |
| Bydlowski, SP; Clavé, MM; Lopes, AA; Maeda, NY; Thomaz, AM | 1 |
| Beaussier, M; Boucau, C; Cosserat, J; Denet, C; Mascitti, P; Montandrau, O; Philip, I | 1 |
| Cohen, JL; Krishnan, US; Nees, SN; Rosenzweig, EB; Valencia, GA | 1 |
| Baldus, S; Dumitrescu, D; Gerhardt, F; Hellmich, M; Kramer, T; Orlova, K; Rosenkranz, S; Ten Freyhaus, H | 1 |
| Akers, S; Ambrosini, R; Champion, HC; Glickman, S; Haight, D; Lachant, DJ; Meoli, DF; Staicu, S; White, RJ | 1 |
| El-Kersh, K; Fraig, M; Perez, RL; Smith, JS | 1 |
| Mohindroo, NK; Negi, PC; Sharma, DR; Thakur, A; Thakur, JS; Thakur, S | 1 |
| Doran, AK; Hill, W; Shapiro, S; Traiger, G; Zhang, L | 1 |
| Chaumais, MC; Humbert, M; Montani, D; Perrin, S; Simonneau, G; Sitbon, O | 1 |
| Chalam, KV; Grover, S; Murthy, RK; Perez, L; Priluck, JC | 1 |
| Izzo, A; Khatwa, U; Kothare, SV; Kulik, T; McSweeney, J | 1 |
| Beheshtian, E; Sabri, MR | 1 |
| Channick, R; Klinger, JR; Preston, I | 1 |
| Ioakeimidis, N; Kostis, JB | 1 |
| Hayashi, H; Hirai, K; Itoh, K; Ono, Y; Todoroki, K; Tomatsuri, M; Toyo'oka, T; Yamada, H; Yamada, Y; Yokoyama, Y | 1 |
| Derderian, SC; Etemadi, M; Fineman, JR; Gong, W; Iqbal, C; Johengen, M; Miniati, D; Oishi, P; Schecter, SC; Shue, EH | 1 |
| Chen, J; Huang, T; Huang, X; Huang, Y; Xia, C; Zhang, C; Zhang, G; Zhuang, J | 1 |
| Gao, H; Jiang, B; Zhao, W; Zhuang, Y | 1 |
| Hirashiki, A; Kondo, T; Murohara, T | 1 |
| Behr, J; Geiseler, J; Huppmann, P; Ihle, F; Leuchte, HH; Meis, T; Neurohr, C; Tufman, A; von Wulffen, W; Zimmermann, GS | 1 |
| Watanabe, H | 1 |
| Brusselle, G | 1 |
| Goudie, AR; Hopkinson, PJ; Lipworth, BJ; Struthers, AD; Wei, L | 1 |
| Bourge, RC; Burger, CD; Durst, L; Franco, V; Frantz, RP; McDevitt, S; Oudiz, RJ; Walker, S; Waxman, AB | 1 |
| Akita, C; Hirono, K; Ichida, F; Ishida, K; Kohno, H; Nakamura, T; Ozawa, S; Taguchi, M; Yoshimura, N | 1 |
| Baloira Villar, A; Núñez Fernández, M; Pousada Fernández, G; Valverde Pérez, D | 1 |
| Hassoun, PM; Mathai, SC; Puhan, MA; Wise, RA; Zhou, Y | 1 |
| Bowles, EA; Ellsworth, ML; Moody, GN; Sprague, RS; Stephenson, AH; Yeragunta, Y | 1 |
| Bach, L; Geenen, D; Raghavan, A; Raj, JU; Ramchandran, R; Sun, M; Yang, Q | 1 |
| Chen, J; Huang, T; Huang, X; Huang, Y; Wu, S; Xia, C; Yao, H; Zhang, C; Zhang, G; Zhuang, J | 1 |
| Chikazawa, S; Hori, Y; Hoshi, F; Itoh, N; Kanai, K; Kondo, C; Matsui, M; Okano, S; Yamagishi, M | 1 |
| Egenlauf, B; Ehlken, N; Grünig, E; Harzheim, D; Lichtblau, M; Marra, A; Pinado, FP | 1 |
| Altamura, S; Bärtsch, P; Dehnert, C; Maggiorini, M; Mairbäurl, H; Muckenthaler, MU; Theurl, I; Weiss, G | 1 |
| Ala, S; Babazadeh, K; Rafati, M; Saeedi, M; Shiran, M; Shiva, A; Zamani, H | 1 |
| Nikpour, M; Proudman, SM; Stevens, WM; Thakkar, V | 1 |
| Bentley, S; Magee, AG; Makhecha, S | 1 |
| Fujita, J; Fukuda, K; Kataoka, M; Kimura, M; Kuwana, M; Ono, T; Satoh, T; Takei, M; Tamura, Y; Yamamoto, T | 1 |
| Bednorz, M; Ghofrani, HA; Grimminger, F; Parajuli, N; Pichl, A; Schermuly, RT; Seeger, W; Seimetz, M; Weissmann, N | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kinugawa, K; Ko, T; Komuro, I; Maki, H; Minatsuki, S; Muraoka, H; Nitta, D; Yao, A | 1 |
| Peacock, AJ; Vizza, CD; Zamboni, W | 1 |
| Barberà, JA; Blair, C; Frost, AE; Galiè, N; Ghofrani, HA; Gillies, H; Grünig, E; Harris, JH; Hoeper, MM; Langley, J; McLaughlin, VV; Miller, KL; Oudiz, RJ; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiery, JL; Vonk-Noordegraaf, A; White, RJ | 1 |
| Chin, K; Corona-Villalobos, CP; Damico, R; Gashouta, MA; Girgis, RE; Hassoun, PM; Housten, T; Hulme, OL; Khair, R; Kolb, TM; Lechtzin, N; Mathai, SC; Minai, OA; Pisanello, C; Pullins, EH; Sato, T; Tedford, RJ; Torres, F; Zamanian, RT; Zimmerman, SL | 1 |
| Ando, K; Hoshika, Y; Ienaga, H; Kimura, T; Kuraishi, H; Morio, Y; Nagaoka, T; Takahashi, K; Tsutsumi, T | 1 |
| Khanna, D; McLaughlin, V | 1 |
| Burhenne, J; Enderle, Y; Friedrich, J; Grünig, E; Haefeli, WE; Meid, AD; Wilkens, H | 1 |
| Blouin, J; Coyle, D; Coyle, K; Innes, M; Jabr, MF; Lee, K; Mielniczuk, L; Swiston, J; Tran, K | 1 |
| Jujo, T; Kasai, H; Kato, F; Nishimura, R; Sakao, S; Sekine, A; Shigeta, A; Suda, R; Sugiura, T; Tanabe, N; Tatsumi, K | 1 |
| Cleveland, JM; Minai, OA; Rao, Y; Rose, JA; Tonelli, AR | 1 |
| Bauer, F; Bergot, E; Bertoletti, L; Bourdin, A; Bouvaist, H; Chabannes, C; Chaouat, A; Cottin, V; Dauphin, C; De Groote, P; Humbert, M; Jaïs, X; Montani, D; Sattler, C; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Azuma, H; Kajihama, A; Kajino, H; Kamiyama, N; Maeda, J; Nakau, K; Oka, H; Sugimoto, M; Tasaki, Y; Yamagishi, H | 1 |
| Foucher, A; Guilleminault, L; Laurent, S; Paganin, F; Poubeau, P | 1 |
| Jachowicz, R; Krupa, A; Majda, D; Mozgawa, W; Szlęk, J | 1 |
| Cheong, FY; Farber, HW; Gower, AC | 1 |
| Bydlowski, SP; Clavé, MM; Lopes, AA; Maeda, NY | 1 |
| Barberá, JA; Blair, C; Frost, AE; Ghofrani, HA; Harris, JHN; Hoeper, MM; Langley, J; McLaughlin, VV; Miller, KL; Oudiz, RJ; Peacock, AJ; Rosenkranz, S; Rubin, LJ; Simonneau, G; Vachiery, JL; White, RJ | 1 |
| Iranian, M; Jalalian, R; Khafri, S; Moghadamnia, AA; Tamaddoni, A | 1 |
| Barberà, JA; Blair, C; Coghlan, JG; Frost, AE; Galiè, N; Ghofrani, HA; Gillies, H; Harris, JHN; Hoeper, MM; Kuwana, M; Langley, J; McLaughlin, VV; Miller, KL; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiéry, JL | 1 |
| Kobayashi, N; Murakami, M; Tajima, K; Taketsuna, M; Yamazaki, H | 1 |
| Dardi, F; Denton, CP; Esler, A; Galiè, N; Harmon, C; Li, B; Manes, A; Mazzanti, G; Palazzini, M; Varanese, L | 1 |
| Bendayan, D; Kramer, MR; Shitrit, D | 1 |
| Sakuma, M; Shirato, K | 1 |
| Faruqi, S; Fathi, H; Morice, AH | 1 |
| Barst, RJ; Beardsworth, A; Brundage, BH; Chan, M; Frumkin, L; Galiè, N; Ghofrani, HA; Oudiz, RJ; Safdar, Z; Shapiro, S; Simonneau, G; White, RJ | 1 |
| Bernheim, A; Bloch, KE; Brunner-La Rocca, HP; Debrunner, J; Dorschner, L; Fischler, M; Kiencke, S; Maggiorini, M; Mairbäurl, H; Naeije, R | 1 |
| Angalakuditi, M; Beardsworth, A; Chan, M; Pepke-Zaba, J | 1 |
| Chaumais, MC; Humbert, M; Jaïs, X; Montani, D; Natali, D; Price, LC; Savale, L; Simonneau, G; Sitbon, O | 1 |
| Beardsworth, A; Fujita, K; Kato, M; Nakazawa, T; Sawamura, F | 1 |
| Rosenzweig, EB | 1 |
| Berez, PB | 1 |
| Galiè, N; Rubin, LJ; Simonneau, G | 1 |
| Croxtall, JD; Lyseng-Williamson, KA | 1 |
| Humbert, M; Jais, X; Sanchez, O; Simonneau, G; Sitbon, O | 1 |
| Falk, JA; Philip, KJ; Schwarz, ER | 1 |
| Kiliçkesmez, K; Küçükoğlu, MS | 1 |
| Barst, RJ; Beardsworth, A; Brundage, BH; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G; Sundin, DP | 1 |
| Levin, YD; White, RJ | 1 |
| Klinger, JR | 1 |
| Arif, SA; Poon, H | 1 |
| Aizawa, T; Hatano, M; Inaba, T; Kinugawa, K; Maki, H; Nagai, R; Shiga, T; Yamashita, T; Yao, A | 1 |
| Fahim, M; Kotwani, A; Rashid, M | 2 |
| Belardinelli, L; Liang, F; Shryock, J; Yang, S; Yao, L | 1 |
| Frey, MK; Lang, I | 1 |
| Calderbank, M; Ivy, DD; Takatsuki, S | 1 |
| Allanore, Y | 1 |
| Carbognani, D; Chachques, JC; Dai, G; Feng, M; Lila, N; Nour, S; Wu, G; Yang, D | 1 |
| Lam, D; Mathai, SC; Puhan, MA; Wise, RA | 1 |
| Ahmad, S; Brown, AW; Lemma, M; Nathan, SD; Shlobin, OA; Weir, N | 1 |
| Barst, RJ; Beardsworth, A; Botros, FT; Brundage, BH; Chan, M; Galiè, N; Ghofrani, HA; Oudiz, RJ; Simonneau, G | 1 |
| Ji, YQ; Liu, CP; Lu, WX; Zeng, Q; Zhang, WH; Zhang, YJ | 1 |
| Bregel, D; Kaiser, R; Kraemer, T; Rust, KY; Wilkens, H; Wilske, J | 1 |
| Schwarz, ER; Udeoji, DU | 1 |
| Gaudó Navarro, J; Sueiro Bendito, A | 1 |
| Ghofrani, HA; Grimminger, F; Haredza, P; Karadaş, B; Olschewski, H; Reichenberger, F; Schermuly, RT; Seeger, W; Voswinckel, R; Weissmann, N | 1 |
| Beasley, A; Blount, MA; Corbin, JD; Francis, SH | 1 |
| Affuso, F; Di Conza, P; Fazio, S; Guardasole, V; Palmieri, EA | 1 |
| Brown, JW; Fiore, AC; Meldrum, DR; Sheridan, BC; Tsai, BM; Turrentine, MW; Wang, M | 1 |
| Chetboul, V; Gouni, V; Nicolle, AP; Pouchelon, JL; Serres, F; Tissier, R | 1 |
| Ghofrani, HA; Grimminger, F | 1 |
| Bremer, H; Deibert, P; Kreisel, W; Kurz-Schmieg, AK; Roessle, M | 1 |
| Kukreja, RC | 1 |
| de Carvalho, AC; Fernandes, CJ; Hovnanian, AL; Jardim, C; Lapa, M; Souza, R | 1 |
| Geok-Mui, MK; Poh-Hoon, MC; Tay, EL; Yip, J | 1 |
| Kim, HS; Lee, HB; Park, JH; Park, JK; Park, SJ | 1 |
| Bernheim, AM; Brunner-La Rocca, HP; Debrunner, J; Dorschner, L; Fischler, M; Kiencke, S; Maggiorini, M; Mairbäurl, H | 1 |
| Belik, J; Colvero, M; Fiori, H; Fiori, RM; Tessler, RB; Zadinello, M | 1 |
27 review(s) available for tadalafil and Hypertension, Pulmonary
| Article | Year |
|---|---|
Phosphodiesterase-5 inhibitors in pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes.
Topics: Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Fetal Distress; Fetal Growth Retardation; Humans; Hypertension, Pulmonary; Infant, Newborn; Phosphodiesterase 5 Inhibitors; Pregnancy; Sildenafil Citrate; Tadalafil | 2022 |
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Topics: Adult; Antihypertensive Agents; Endothelin Receptor Antagonists; Endothelins; Guanosine Monophosphate; Heart Failure; Humans; Hypertension, Pulmonary; Infant, Newborn; Nitric Oxide; Pulmonary Arterial Hypertension; Tadalafil; United States | 2022 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
Ambrisentan: a review of its use in pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Randomized Controlled Trials as Topic; Tadalafil | 2017 |
Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database.
Topics: Adverse Drug Reaction Reporting Systems; Clinical Trials as Topic; Humans; Hypertension, Pulmonary; Pharmacovigilance; Phosphodiesterase 5 Inhibitors; Pulmonary Wedge Pressure; Sildenafil Citrate; Tadalafil; World Health Organization | 2018 |
Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment.
Topics: Adult; Animals; Carbolines; Child; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
"Nocturnal seizures" in idiopathic pulmonary arterial hypertension.
Topics: Carbolines; Cardiac Output, Low; Child, Preschool; Diagnosis, Differential; Drug Therapy, Combination; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Oxygen Inhalation Therapy; Parasomnias; Seizures; Severity of Illness Index; Sleep Apnea Syndromes; Tadalafil; Treatment Outcome; Warfarin | 2013 |
Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
Topics: Administration, Oral; Carbolines; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Topics: Animals; Carbolines; Cardiovascular Diseases; Cardiovascular System; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2014 |
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Scleroderma, Systemic; Tadalafil; Treatment Outcome | 2015 |
Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
Topics: Animals; Child; Cyclic GMP; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2015 |
Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
Topics: Endothelin A Receptor Antagonists; Exercise Tolerance; Humans; Hypertension, Pulmonary; Pharmacovigilance; Phenylpropionates; Pyridazines; Tadalafil; Treatment Outcome; Vasodilator Agents | 2015 |
[Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension].
Topics: Carbolines; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2008 |
Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Topics: Algorithms; Carbolines; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Veno-Occlusive Disease; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2009 |
Tadalafil for the treatment of pulmonary arterial hypertension.
Topics: Carbolines; Erectile Dysfunction; Half-Life; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
Tadalafil: in pulmonary arterial hypertension.
Topics: Carbolines; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Tadalafil | 2010 |
[Guidelines for the diagnosis and treatment of pulmonary hypertension].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Piperazines; Practice Guidelines as Topic; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vasodilator Agents | 2010 |
The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Blood Pressure; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Administration Schedule; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome; Vasodilator Agents | 2010 |
[Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension].
Topics: Carbolines; Drug Therapy, Combination; Hemodynamics; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2010 |
Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Carbolines; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Kidney; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Signal Transduction; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents | 2011 |
Tadalafil for the treatment of pulmonary arterial hypertension.
Topics: Blood Pressure; Carbolines; Cyclic GMP; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Natriuretic Peptides; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Signal Transduction; Tadalafil; Treatment Outcome; Vasodilator Agents | 2011 |
Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
Topics: Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Interactions; Humans; Hypertension, Pulmonary; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Tadalafil; Vasodilator Agents | 2011 |
Tadalafil for the treatment of pulmonary arterial hypertension.
Topics: Carbolines; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Tadalafil; Vasodilator Agents | 2012 |
Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Arterial Pressure; Carbolines; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Tadalafil; Treatment Outcome | 2013 |
[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension].
Topics: Carbolines; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Drug Interactions; Exercise Tolerance; Humans; Hypertension, Pulmonary; Molecular Structure; Phosphodiesterase 5 Inhibitors; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Second Messenger Systems; Tadalafil | 2011 |
[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Hypertension, Pulmonary; Imidazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2006 |
23 trial(s) available for tadalafil and Hypertension, Pulmonary
| Article | Year |
|---|---|
Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study.
Topics: Animals; Dog Diseases; Dogs; Double-Blind Method; Electrocardiography; Female; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prospective Studies; Random Allocation; Severity of Illness Index; Sildenafil Citrate; Surveys and Questionnaires; Tadalafil; Treatment Outcome | 2019 |
Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
Topics: Adult; Antihypertensive Agents; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Elapid Venoms; Endothelin A Receptor Antagonists; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, C-Type; Outcome Assessment, Health Care; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Survival; Tadalafil; Treatment Outcome | 2017 |
Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Topics: Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Contraction; Observer Variation; Phenylpropionates; Prospective Studies; Pyridazines; Scleroderma, Limited; Tadalafil; Treatment Outcome; Ventricular Dysfunction, Right | 2018 |
Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts.
Topics: Cardiac Surgical Procedures; Child, Preschool; Echocardiography; Female; Heart Defects, Congenital; Heart Septal Defects, Ventricular; Humans; Hypertension, Pulmonary; Infant; Iran; Length of Stay; Male; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Sildenafil Citrate; Tadalafil; Treatment Outcome | 2017 |
Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score.
Topics: Aged; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Pyridazines; Registries; Risk Assessment; Survival Rate; Tadalafil | 2018 |
Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adolescent; Adult; Cardiac Catheterization; Child; Dose-Response Relationship, Drug; Echocardiography; Female; Follow-Up Studies; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Circulation; Pulmonary Wedge Pressure; Retrospective Studies; Sildenafil Citrate; Tadalafil; Treatment Outcome; Young Adult | 2019 |
Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Carbolines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Outcome Assessment, Health Care; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Tadalafil; Treatment Outcome; Young Adult | 2014 |
Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.
Topics: Aged; Carbolines; Double-Blind Method; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Pulmonary Disease, Chronic Obstructive; Quality of Life; Scotland; Surveys and Questionnaires; Tadalafil; Treatment Outcome | 2014 |
Sex differences in response to tadalafil in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Carbolines; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Maryland; Middle Aged; Prevalence; Pulmonary Wedge Pressure; Quality of Life; Sex Distribution; Sex Factors; Tadalafil; Treatment Outcome; Vasodilator Agents | 2015 |
[Effects of iloprost combined with low dose tadalafil in adult congenital heart disease patients with severe pulmonary arterial hypertension: a single-center, open-label controlled study].
Topics: Adolescent; Adult; Carbolines; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Iloprost; Male; Middle Aged; Tadalafil; Treatment Outcome; Young Adult | 2014 |
Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Intravenous; Administration, Oral; Animals; Carbolines; Cross-Over Studies; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Hemodynamics; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Random Allocation; Tadalafil; Time Factors; Vascular Resistance; Vasoconstrictor Agents | 2014 |
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Carbolines; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypertension, Pulmonary; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phenylpropionates; Pyridazines; Risk Factors; Tadalafil | 2015 |
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
Topics: Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Phenylpropionates; Proportional Hazards Models; Pulmonary Artery; Pyridazines; Tadalafil; Treatment Outcome | 2016 |
Comparing the Efficacy of Tadalafil Versus Placebo on Pulmonary Artery Systolic Pressure and Right Ventricular Function in Patients with Beta-Thalassaemia Intermedia.
Topics: Adult; beta-Thalassemia; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Artery; Tadalafil; Ventricular Function, Right | 2017 |
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Topics: Adult; Aged; Antihypertensive Agents; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Mixed Connective Tissue Disease; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Scleroderma, Systemic; Tadalafil | 2017 |
Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease.
Topics: Connective Tissue Diseases; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Physical Examination; Tadalafil; Treatment Outcome; Vasodilator Agents | 2017 |
Tadalafil therapy for pulmonary arterial hypertension.
Topics: Adult; Aged; Bosentan; Carbolines; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Quality of Life; Sulfonamides; Tadalafil; Treatment Outcome | 2009 |
Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema.
Topics: Adult; Altitude Sickness; Anti-Inflammatory Agents; Carbolines; Carbon Dioxide; Dexamethasone; Double-Blind Method; Echocardiography; Exercise Test; Female; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Oxygen; Phosphodiesterase Inhibitors; Pulmonary Edema; Pulmonary Wedge Pressure; Tadalafil; Vasoconstriction | 2009 |
Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension.
Topics: Carbolines; Double-Blind Method; Exercise Test; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Placebos; Quality of Life; Tadalafil | 2009 |
Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Tadalafil; Treatment Outcome | 2011 |
Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
Topics: Adult; Aged; Analysis of Variance; Antihypertensive Agents; Bosentan; Carbolines; Double-Blind Method; Drug Administration Schedule; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Sulfonamides; Tadalafil; Treatment Outcome; Vasodilator Agents | 2012 |
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Adult; Aged; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Hypertension, Pulmonary; Imidazoles; Male; Middle Aged; Oxygen; Phosphoric Diester Hydrolases; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride; Vascular Resistance; Vasodilator Agents | 2004 |
Acute changes in pulmonary artery pressures due to exercise and exposure to high altitude do not cause left ventricular diastolic dysfunction.
Topics: Adult; Altitude; Blood Flow Velocity; Carbolines; Dexamethasone; Diastole; Echocardiography, Doppler; Exercise; Exercise Test; Female; Follow-Up Studies; Glucocorticoids; Humans; Hypertension, Pulmonary; Male; Mountaineering; Myocardial Contraction; Phosphodiesterase Inhibitors; Prognosis; Pulmonary Edema; Pulmonary Wedge Pressure; Reference Values; Rest; Tadalafil; Ventricular Dysfunction, Left | 2007 |
92 other study(ies) available for tadalafil and Hypertension, Pulmonary
| Article | Year |
|---|---|
Optimization of Chromeno[2,3- c]pyrrol-9(2 H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure-Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Animals; Crystallography, X-Ray; ERG1 Potassium Channel; Hypertension, Pulmonary; Microsomes, Liver; Models, Molecular; Molecular Structure; Phosphodiesterase 5 Inhibitors; Protein Conformation; Pulmonary Artery; Structure-Activity Relationship | 2018 |
Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Topics: Animals; Dogs; Drug Design; Female; Half-Life; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Sildenafil Citrate; Structure-Activity Relationship; Substrate Specificity | 2019 |
Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
Topics: Adolescent; Antihypertensive Agents; Child; Child, Preschool; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyridazines; Retrospective Studies; Tadalafil; Treatment Outcome | 2022 |
A 65-Year-Old Man With Weight Loss, Peripheral Neuropathy, and Lower Extremity Swelling.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Edema; Exercise Tolerance; Humans; Hypertension, Pulmonary; Lenalidomide; Male; Neoplasms, Plasma Cell; Peripheral Nervous System Diseases; Phosphodiesterase 5 Inhibitors; POEMS Syndrome; Positron Emission Tomography Computed Tomography; Stem Cell Transplantation; Syncope; Tadalafil; Weight Loss | 2022 |
Modification Tadalafil and Macitentan tablets to aerosol.
Topics: Aerosols; Humans; Hypertension, Pulmonary; Particle Size; Pyrimidines; Sulfonamides; Tablets; Tadalafil | 2022 |
CRISPR-mediated Bmpr2 point mutation exacerbates late pulmonary vasculopathy and reduces survival in rats with experimental pulmonary hypertension.
Topics: Animals; Bone Morphogenetic Protein Receptors, Type II; Clustered Regularly Interspaced Short Palindromic Repeats; Fibrosis; Humans; Hypertension, Pulmonary; Lung; Mice; Monocrotaline; Point Mutation; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Tadalafil | 2022 |
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.
Topics: Carbolines; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Purines; Sildenafil Citrate; Tadalafil | 2023 |
A case-control study of phosphodiesterase-5 inhibitor use and Alzheimer's disease and related dementias among male and female patients aged 65 years and older supporting the need for a phase III clinical trial.
Topics: Aged; Alzheimer Disease; Case-Control Studies; Cyclic Nucleotide Phosphodiesterases, Type 5; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil | 2023 |
A successful treatment of tadalafil in incontinentia pigmenti with pulmonary hypertension.
Topics: Exons; Female; Humans; Hypertension, Pulmonary; I-kappa B Kinase; Incontinentia Pigmenti; Infant, Newborn; NF-kappa B; Seizures; Sequence Deletion; Skin; Tadalafil | 2020 |
Fibromuscular dysplasia and coronary artery fistula: links to pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Coronary Artery Disease; Female; Fibromuscular Dysplasia; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Sildenafil Citrate; Tadalafil; Vascular Fistula; Vasodilator Agents | 2020 |
Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
Topics: Adult; Aged; Antihypertensive Agents; Arterial Pressure; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Lung Transplantation; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pyridazines; Retrospective Studies; Sarcoidosis, Pulmonary; Tadalafil; Treatment Outcome | 2020 |
Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION.
Topics: Humans; Hypertension, Pulmonary; Pulmonary Arterial Hypertension; Tadalafil | 2021 |
Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan.
Topics: Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Pulmonary Veins; Sildenafil Citrate; Sulfonamides; Tadalafil; Vardenafil Dihydrochloride; Vasodilation; Vasodilator Agents | 2017 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Hypertension, Pulmonary; Infant; Japan; Male; Phosphodiesterase 5 Inhibitors; Product Surveillance, Postmarketing; Tadalafil | 2017 |
The Nitric Oxide Pathway-A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension.
Topics: Cyclic GMP; Drug Therapy, Combination; Endothelins; Enzyme Activators; Humans; Hypertension, Pulmonary; Molecular Targeted Therapy; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Precision Medicine; Pyrazoles; Pyrimidines; Signal Transduction; Sildenafil Citrate; Tadalafil | 2017 |
Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study).
Topics: Adult; Aged; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension, Pulmonary; Italy; Male; Middle Aged; Phenylpropionates; Pyridazines; Retrospective Studies; Tadalafil; Treatment Outcome; Vascular Resistance | 2018 |
Pulmonary Hypertension and Its Response to Treatment in a Patient with Kyphosis-related Alveolar Hypoventilation.
Topics: Aged; Humans; Hypertension, Pulmonary; Hypoventilation; Kyphosis; Male; Noninvasive Ventilation; Tadalafil; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2018 |
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Topics: Aged; Aged, 80 and over; Chronic Disease; Drug Substitution; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Tadalafil | 2018 |
Can results from a Japanese pulmonary hypertension registry have an impact on Western guidelines?
Topics: Angioplasty, Balloon; Cyclic Nucleotide Phosphodiesterases, Type 1; Drug Therapy, Combination; Endarterectomy; Epoprostenol; Genome-Wide Association Study; Hemodynamics; Humans; Hypertension, Pulmonary; Japan; Molecular Targeted Therapy; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Practice Guidelines as Topic; Pulmonary Embolism; Pyridazines; Randomized Controlled Trials as Topic; Registries; Sildenafil Citrate; Tadalafil | 2018 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
Pulmonary arterial hypertension in patient treated for multiple sclerosis with 4-aminopyridine.
Topics: 4-Aminopyridine; Antihypertensive Agents; Dyspnea; Female; Humans; Hypertension, Pulmonary; Middle Aged; Multiple Sclerosis; Phenylpropionates; Potassium Channel Blockers; Pyridazines; Tadalafil | 2019 |
Laparoscopic Rectopexy in a Patient With Pulmonary Hypertension Associated With Scleroderma: A Case Report.
Topics: Aged; Antihypertensive Agents; Bosentan; Female; Head-Down Tilt; Humans; Hypertension, Pulmonary; Laparoscopy; Preoperative Care; Rectal Prolapse; Tadalafil; Treatment Outcome | 2019 |
Sildenafil Use in Children with Pulmonary Hypertension.
Topics: Adolescent; Bronchopulmonary Dysplasia; Child; Child, Preschool; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hernias, Diaphragmatic, Congenital; Humans; Hypertension, Pulmonary; Infant; Infant, Newborn; Male; Sildenafil Citrate; Tadalafil; Treatment Outcome; Vasodilator Agents | 2019 |
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Topics: Aged; Cardiac Catheterization; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Retrospective Studies; Stroke Volume; Tadalafil; Time Factors; Treatment Outcome; Vascular Resistance; Ventricular Function, Right | 2019 |
Combination therapy improves vascular volume in female rats with pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Female; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Monocrotaline; Phenylpropionates; Pneumonectomy; Pulmonary Artery; Pyridazines; Rats; Rats, Sprague-Dawley; Tadalafil; Vascular Remodeling; Vasoconstriction; Ventricular Dysfunction, Right; X-Ray Microtomography | 2019 |
Smoking-related interstitial fibrosis (SRIF) and pulmonary hypertension.
Topics: Antihypertensive Agents; Biopsy; Bosentan; Carbolines; Cardiac Catheterization; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Fibrosis; Respiratory Function Tests; Smoking; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2013 |
Hearing loss with phosphodiesterase-5 inhibitors: a prospective and objective analysis with tadalafil.
Topics: Adult; Audiometry, Pure-Tone; Carbolines; Erectile Dysfunction; Evoked Potentials, Auditory, Brain Stem; Female; Follow-Up Studies; Hearing; Hearing Loss, Sensorineural; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Tadalafil | 2013 |
Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carbolines; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil | 2013 |
Tadalafil for benign prostatic hyperplasia.
Topics: Adult; Carbolines; Drug Approval; Erectile Dysfunction; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Lower Urinary Tract Symptoms; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil | 2013 |
Acute, bilateral, concurrent central retinal artery occlusion in sickle cell disease after use of tadalafil (Cialis).
Topics: Acute Disease; Adult; Anemia, Sickle Cell; Carbolines; Familial Primary Pulmonary Hypertension; Female; Fluorescein Angiography; Humans; Hypertension, Pulmonary; Papilledema; Phosphodiesterase 5 Inhibitors; Retinal Artery Occlusion; Tadalafil; Tomography, Optical Coherence | 2013 |
Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Carbolines; Child; Child, Preschool; Dose-Response Relationship, Drug; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Male; Oxygen Consumption; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Wedge Pressure; Purines; Retrospective Studies; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Walking; Young Adult | 2014 |
Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension.
Topics: Bosentan; Carbolines; Child; Child, Preschool; Chromatography, Liquid; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Infant; Male; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Tandem Mass Spectrometry | 2014 |
Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia.
Topics: Animals; Carbolines; Cyclic GMP; Disease Models, Animal; Drug Evaluation, Preclinical; Enzyme Induction; Female; Fetal Diseases; Fetal Therapies; Hernia, Diaphragmatic; Hernias, Diaphragmatic, Congenital; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Maternal-Fetal Exchange; Nitric Oxide Synthase Type III; Organ Size; Phosphodiesterase 5 Inhibitors; Pregnancy; Random Allocation; Second Messenger Systems; Sheep; Tadalafil | 2014 |
Effects of low doses of aerosolized iloprost combined with tadalafil in treatment of adult congenital heart disease with severe pulmonary arterial hypertension.
Topics: Administration, Inhalation; Adult; Carbolines; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Iloprost; Male; Tadalafil; Young Adult | 2014 |
Combination therapy adding tadalafil to existing ambrisentan in patients with pulmonary arterial hypertension.
Topics: Carbolines; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Tadalafil | 2014 |
Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
Topics: Aged; Aged, 80 and over; Carbolines; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Interstitial; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Pilot Projects; Piperazines; Purines; Respiratory Function Tests; Sildenafil Citrate; Sulfonamides; Tadalafil; Walking | 2014 |
Should we pursue pulmonary vasodilation in patients with COPD?
Topics: Carbolines; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Quality of Life; Tadalafil | 2014 |
Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Arterial Pressure; Carbolines; Drug Substitution; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Piperazines; Prospective Studies; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Surveys and Questionnaires; Tadalafil; Time Factors; Treatment Outcome; United States; Vasodilator Agents; Young Adult | 2014 |
Plasma concentrations of tadalafil in children with pulmonary arterial hypertension.
Topics: Adolescent; Aging; Antihypertensive Agents; Bosentan; Carbolines; Child; Child, Preschool; Female; Humans; Hypertension, Pulmonary; Infant; Male; Sulfonamides; Tadalafil; Vasodilator Agents | 2014 |
Clinical and molecular study of 4 cases of pulmonary hypertension associated with sarcoidosis.
Topics: Bone Morphogenetic Protein Receptors, Type II; Bosentan; Disease Progression; Epoprostenol; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Kv1.5 Potassium Channel; Male; Middle Aged; Mutation; Phenylpropionates; Point Mutation; Pyridazines; Respiratory Function Tests; RNA, Messenger; Sarcoidosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome | 2015 |
Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension.
Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Antihypertensive Agents; Carbolines; Cyclic AMP; Drug Synergism; Epoprostenol; Erythrocytes; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Purinones; Tadalafil; Young Adult | 2015 |
PKG-1α leucine zipper domain defect increases pulmonary vascular tone: implications in hypoxic pulmonary hypertension.
Topics: Animals; Carbolines; Cell Hypoxia; Cells, Cultured; Cyclic GMP-Dependent Protein Kinase Type I; Drug Evaluation, Preclinical; Female; Gene Expression; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Muscle, Smooth, Vascular; Mutation; Myocytes, Smooth Muscle; Pulmonary Artery; Pulmonary Circulation; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Tadalafil; Vasodilation; Vasodilator Agents; Ventricular Remodeling | 2014 |
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
Topics: Aged; Antihypertensive Agents; Arterial Pressure; Carbolines; Drug Substitution; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2015 |
Increased hepcidin levels in high-altitude pulmonary edema.
Topics: Altitude; Altitude Sickness; Arterial Pressure; Carbolines; Dexamethasone; Hepcidins; Humans; Hypertension, Pulmonary; Hypoxia; Interleukin-6; Iron; Lung; Tadalafil; Vasoconstriction | 2015 |
Oral Tadalafil in Children with Pulmonary Arterial Hypertension.
Topics: Administration, Oral; Arterial Pressure; Child, Preschool; Female; Humans; Hypertension, Pulmonary; Infant; Iran; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Sildenafil Citrate; Tadalafil | 2016 |
Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Exercise Test; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pilot Projects; Prostaglandins; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance; Young Adult | 2015 |
Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
Topics: Animals; Benzamides; Cyclic AMP; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Hypertension, Pulmonary; Lung; Lung Compliance; Macrophages, Alveolar; Male; Mice; Mice, Inbred C57BL; Phosphodiesterase 4 Inhibitors; Phosphodiesterase 5 Inhibitors; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema; Pyridines; Smoke; Smoking; Tadalafil | 2015 |
A case of interferon-α-induced pulmonary arterial hypertension after living donor liver transplantation.
Topics: Antihypertensive Agents; Arterial Pressure; Drug Therapy, Combination; Epoprostenol; Humans; Hypertension, Pulmonary; Immunologic Factors; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Pulmonary Artery; Tadalafil; Treatment Outcome | 2016 |
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
Topics: Drug Therapy, Combination; Female; Heart Ventricles; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Natriuretic Peptide, Brain; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prospective Studies; Pyridazines; Scleroderma, Systemic; Stroke Volume; Tadalafil; Ultrasonography; Vascular Resistance | 2015 |
Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension.
Topics: Aged; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Female; Forced Expiratory Volume; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Pulmonary Diffusing Capacity; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents; Vital Capacity | 2015 |
Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!
Topics: Female; Humans; Hypertension, Pulmonary; Male; Phenylpropionates; Pyridazines; Scleroderma, Systemic; Tadalafil | 2015 |
Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension.
Topics: Bosentan; Chromatography, Liquid; Dried Blood Spot Testing; Humans; Hypertension, Pulmonary; Limit of Detection; Phenylpropionates; Pyridazines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil; Tandem Mass Spectrometry | 2015 |
Ambrisentan (Letairis) and tadalafil (Adcirca) for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Drug Approval; Drug Therapy, Combination; Humans; Hypertension, Pulmonary; Phenylpropionates; Pyridazines; Tadalafil; United States; United States Food and Drug Administration | 2016 |
Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.
Topics: Administration, Oral; Cost-Benefit Analysis; Humans; Hypertension, Pulmonary; Markov Chains; Quality-Adjusted Life Years; Sildenafil Citrate; Tadalafil | 2016 |
Synergistic Effects of ACE Insertion/Deletion and GNB3 C825T Polymorphisms on the Efficacy of PDE-5 Inhibitor in Patients with Pulmonary Hypertension.
Topics: Adult; Aged; Female; Heterotrimeric GTP-Binding Proteins; Humans; Hypertension, Pulmonary; INDEL Mutation; Male; Middle Aged; Peptidyl-Dipeptidase A; Phosphodiesterase 5 Inhibitors; Polymorphism, Genetic; Retrospective Studies; Sildenafil Citrate; Tadalafil; Treatment Outcome | 2016 |
Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials.
Topics: Age Factors; Aged; Antihypertensive Agents; Connective Tissue Diseases; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Multivariate Analysis; Phenotype; Pulmonary Wedge Pressure; Randomized Controlled Trials as Topic; Tadalafil; Treatment Outcome; Vasodilator Agents; Walk Test | 2016 |
Initial dual oral combination therapy in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Diethylpropion; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Patient Safety; Phenylpropionates; Pyridazines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Tadalafil; Time Factors; Treatment Outcome | 2016 |
Pharmacokinetics of drugs for pediatric pulmonary hypertension.
Topics: Administration, Oral; Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Infant; Male; Phosphodiesterase 5 Inhibitors; Prospective Studies; Pulmonary Wedge Pressure; Sulfonamides; Tadalafil; Young Adult | 2016 |
Pulmonary arterial hypertension in adult onset Still's disease: a case report of a severe complication.
Topics: Adrenal Cortex Hormones; Adult; Antihypertensive Agents; Antirheumatic Agents; Echocardiography; Female; Humans; Hypertension, Pulmonary; Interleukin 1 Receptor Antagonist Protein; Phenylpropionates; Pyridazines; Still's Disease, Adult-Onset; Tadalafil; Tomography, X-Ray Computed; Young Adult | 2016 |
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
Topics: Bosentan; Drug Design; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Rare Diseases; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil.
Topics: Aged; Down-Regulation; Extracellular Matrix; Female; Golgi Apparatus; Humans; Hypertension, Pulmonary; Immunity, Innate; Interleukin-12; Male; Microarray Analysis; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase 5 Inhibitors; Pilot Projects; Potassium Channels, Voltage-Gated; Scleroderma, Systemic; Signal Transduction; Tadalafil; Transcriptome; Treatment Outcome; Up-Regulation; Walk Test | 2017 |
Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension.
Topics: Cell Hypoxia; Female; Humans; Hypertension, Pulmonary; Male; Tadalafil; Thrombomodulin; Treatment Outcome; Vasodilator Agents | 2016 |
Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data.
Topics: Adolescent; Adult; Aged; Female; Humans; Hypertension, Pulmonary; Japan; Male; Marketing; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Tadalafil; Young Adult | 2017 |
Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.
Topics: Adult; Antihypertensive Agents; Carbolines; Drug Therapy, Combination; Eisenmenger Complex; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Middle Aged; Phosphodiesterase Inhibitors; Pilot Projects; Prospective Studies; Tadalafil | 2008 |
Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Tadalafil; Thiophenes; Treatment Outcome; Vasodilator Agents | 2010 |
Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
Topics: Animals; Blood Gas Analysis; Carbolines; Cyclic GMP; Disease Progression; Dose-Response Relationship, Drug; Hemodynamics; Hydrogen-Ion Concentration; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Organ Size; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Poisons; Pulmonary Circulation; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Survival; Tadalafil | 2009 |
Tadalafil (Adcirca) for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Carbolines; Drug Costs; Drug Interactions; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome | 2009 |
The successful use of phosphodiesterase type 5 inhibitors to treat the syndrome of cor pulmonale and prerenal azotemia with diuresis of anasarca (CorPRADA).
Topics: Azotemia; Blood Pressure; Carbolines; Diuresis; Diuretics; Edema; Glomerular Filtration Rate; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Heart Disease; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2010 |
Phosphodiesterase inhibitors for pulmonary hypertension.
Topics: Carbolines; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Meta-Analysis as Topic; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2010 |
Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Carbolines; Cardiac Output; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography; Electrocardiography; Epoprostenol; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Middle Aged; Sulfonamides; Tadalafil; Vasodilator Agents | 2011 |
Long-acting phosphodiesterase 5 inhibitor, tadalafil, and superoxide dismutase mimetic, tempol, protect against acute hypoxia-induced pulmonary hypertension in rats.
Topics: Animals; Antioxidants; Blood Pressure; Carbolines; Cardiac Output; Cyclic N-Oxides; Heart Rate; Heart Ventricles; Hypertension, Pulmonary; Hypoxia; Malondialdehyde; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Spin Labels; Tadalafil; Vasodilation | 2012 |
Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Carbolines; Cyclic N-Oxides; Disease Models, Animal; Glutathione; Hypertension, Pulmonary; Hypoxia; Inflammation; Lung; Malondialdehyde; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Rats; Rats, Wistar; Spin Labels; Superoxide Dismutase; Tadalafil; Tumor Necrosis Factor-alpha; Ventricular Pressure | 2013 |
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Topics: Animals; Blotting, Western; Carbolines; Disease Models, Animal; Drug Synergism; Endothelin-1; Hypertension, Pulmonary; Male; Phenylpropionates; Pulmonary Artery; Pyridazines; Rats; Rats, Sprague-Dawley; Tadalafil; Vasoconstriction; Vasodilator Agents | 2012 |
Initial experience with tadalafil in pediatric pulmonary arterial hypertension.
Topics: Adolescent; Carbolines; Cardiac Output; Child; Child, Preschool; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Statistics, Nonparametric; Sulfones; Tadalafil; Treatment Outcome; Vascular Resistance | 2012 |
Phosphodiesterase 5 inhibitors in vascular systemic disorders.
Topics: Animals; Carbolines; Disease Models, Animal; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Vascular Diseases; Vasodilator Agents | 2012 |
Intrapulmonary shear stress enhancement: a new therapeutic approach in pulmonary arterial hypertension.
Topics: Analysis of Variance; Animals; Biomarkers; Blotting, Western; Carbolines; Cardiac Output; Disease Models, Animal; Extracorporeal Circulation; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Nitric Oxide Synthase Type III; Shear Strength; Swine; Tadalafil; Vascular Resistance | 2012 |
The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Carbolines; Data Interpretation, Statistical; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Outcome Assessment, Health Care; Phosphodiesterase 5 Inhibitors; Reproducibility of Results; Tadalafil; Treatment Outcome | 2012 |
Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.
Topics: Adult; Aged; Carbolines; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Piperazines; Purines; Retrospective Studies; Severity of Illness Index; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Vasodilator Agents; Young Adult | 2012 |
Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Arterioles; Carbolines; Disease Models, Animal; Drug Therapy, Combination; Familial Primary Pulmonary Hypertension; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Inflammation Mediators; Interleukin-6; Male; Monocrotaline; Phosphodiesterase 5 Inhibitors; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Simvastatin; Tadalafil; Time Factors; Vasodilator Agents | 2012 |
I have had atrial fibrillation for six years and was recently diagnosed with pulmonary arterial hypertension (PAH). I was taken off warfarin (Coumadin) and was put on tadalafil (Adcirca). What can you tell me about PAH and will I be on Adcirca for a long
Topics: Antihypertensive Agents; Blood Pressure; Carbolines; Humans; Hypertension, Pulmonary; Tadalafil; Vasodilator Agents | 2012 |
Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
Topics: Adult; Aged; Antihypertensive Agents; Biotransformation; Carbolines; Chromatography, High Pressure Liquid; Drug Monitoring; Familial Primary Pulmonary Hypertension; Forensic Toxicology; Humans; Hypertension, Pulmonary; Imidazoles; Limit of Detection; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Reproducibility of Results; Sildenafil Citrate; Spectrometry, Mass, Electrospray Ionization; Sulfones; Tadalafil; Tandem Mass Spectrometry; Triazines; Vardenafil Dihydrochloride | 2012 |
High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Chromatography, Gel; Cyclic AMP-Dependent Protein Kinases; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Enzyme Inhibitors; Humans; Hypertension, Pulmonary; Imidazoles; Lung; Myocardium; Piperazines; Rats; Sulfones; Tadalafil; Triazines; Tritium; Vardenafil Dihydrochloride | 2005 |
Tadalafil improves quality of life and exercise tolerance in idiopathic pulmonary arterial hypertension.
Topics: Adult; Carbolines; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Oxygen; Phosphodiesterase Inhibitors; Quality of Life; Tadalafil | 2006 |
Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Evaluation, Preclinical; Gene Expression Regulation; Hypertension, Pulmonary; Hypoxia; Imidazoles; Interleukin-1; Isometric Contraction; Male; Phenylephrine; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Artery; Purines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Tumor Necrosis Factor-alpha; Vardenafil Dihydrochloride; Vasoconstriction | 2006 |
Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog.
Topics: Animals; Carbolines; Dog Diseases; Dogs; Hypertension, Pulmonary; Male; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome | 2006 |
PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Humans; Hypertension, Portal; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil | 2007 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |
Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Humans; Hypertension, Pulmonary; Phosphodiesterase Inhibitors; Severity of Illness Index; Tadalafil | 2006 |
Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
Topics: Adolescent; Adult; Aged; Carbolines; Exercise Tolerance; Female; Half-Life; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil | 2008 |
Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease.
Topics: Carbolines; Exercise Tolerance; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen Consumption; Phosphodiesterase Inhibitors; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Tadalafil | 2007 |
Tadalafil improves oxygenation in a model of newborn pulmonary hypertension.
Topics: Animals; Animals, Newborn; Carbolines; Disease Models, Animal; Echocardiography; Hemodynamics; Hypertension, Pulmonary; Oxygen; Phosphodiesterase Inhibitors; Swine; Tadalafil | 2008 |